Analytical Data
-
Gene name
HLA-A*24:02&B2M&Survivin 2B(AYACNTSTL) Monomer
- Application
-
Alternative Names
svn-2B; Survivin-2B; svn 2B
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59600.1 (G25-T305)&P61769
-
Expression Region
AAA59600.1 (G25-T305)&P61769 (I21-M119)&AYACNTSTL
-
Molecular Weight
55-65 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*24:02 molecule, a prominent human leukocyte antigen (HLA) class I allele, is crucial due to its relevance in immune responses, particularly in the context of cancer immunotherapy. HLA-A*24:02 presents peptides to CD8+ T cells, and its binding capacity can significantly influence the effectiveness of T cell-mediated anti-tumor responses. One peptide of interest is Survivin 2B (AYACNTSTL), derived from the Survivin protein, which is overexpressed in various tumors and is associated with cell proliferation and apoptosis regulation. Recombinant protein technology has been employed to produce monomeric forms of HLA-A*24:02, in complex with the Survivin 2B peptide and beta-2 microglobulin (B2M), to facilitate detailed studies on peptide presentation and T cell activation. This research aims to elucidate the structural and functional dynamics of the HLA-peptide complex, providing insights into T cell recognition and enhancing our understanding of targeted cancer therapies. By characterizing the HLA-A*24:02/B2M/Survivin 2B monomer, the study seeks to improve the design of cancer vaccines and adoptive T cell therapies, ultimately contributing to more effective immunotherapeutic strategies against tumors expressing this specific antigen. These findings could pave the way for novel therapeutic interventions that harness the body's immune system to combat cancer more effectively.
